Inventor · disambiguated record
Dania Birte Reiche
Also filed as: REICHE DANIA · REICHE DANIA B · REICHE DANIA BIRTE
18 granted patents·12 pending applications·71 citations·filing 2002–2025
92Inventor score
Files withBOEHRINGER INGELHEIM VETMEDICA GMBH18SOLVAY PHARM GMBH8ANTEL JOCHEN2REICHE DANIA BIRTE1SOLVAY PHARMACEUTICALS INC1
Top patents by PatentIndex Score
30 records- 0195US11759474B2Use of SGLT-2 inhibitors in the drying-off of non-human mammalsBOEHRINGER INGELHEIM VETMEDICA GMBH·Filed 2020·Granted Sep 19, 2023·2 cites·25 claims
- 0295US11433045B2Treatment of metabolic disorders in canine animalsBOEHRINGER INGELHEIM VETMEDICA GMBH·Filed 2020·Granted Sep 6, 2022·6 cites·13 claims
- 0393US10603300B2Treatment of metabolic disorders in canine animalsBOEHRINGER INGELHEIM VETMEDICA GMBH·Filed 2015·Granted Mar 31, 2020·9 cites·22 claims
- 0488US11896574B2Treatment of metabolic disorders in feline animalsBOEHRINGER INGELHEIM VETMEDICA GMBH·Filed 2020·Granted Feb 13, 2024·3 cites·17 claims
- 0584US10555958B2Combination treatment of SGLT2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animalsBOEHRINGER INGELHEIM VETMEDICA GMBH·Filed 2015·Granted Feb 11, 2020·8 cites·18 claims
- 0683US10864225B2Treatment of metabolic disorders in equine animalsBOEHRINGER INGELHEIM VETMEDICA GMBH·Filed 2016·Granted Dec 15, 2020·5 cites·13 claims
- 0782US7241770B2Hydronopol derivatives as agonists on human ORL1 receptorsSOLVAY PHARM GMBH·Filed 2004·Granted Jul 10, 2007·23 cites·7 claims
- 0881US10688116B2Treatment of metabolic disorders in equine animalsBOEHRINGER INGELHEIM VETMEDICA GMBH·Filed 2015·Granted Jun 23, 2020·7 cites·16 claims
- 0980US12397009B2Use of SGLT-2 inhibitors in the drying-off of non-human mammalsBOEHRINGER INGELHEIM VETMEDICA GMBH·Filed 2023·Granted Aug 26, 2025·0 cites·21 claims
- 1079US10617666B2Treatment of metabolic disorders in feline animalsBOEHRINGER INGELHEIM VETMEDICA GMBH·Filed 2014·Granted Apr 14, 2020·5 cites·18 claims
- 1176US7763607B2Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulatorsSOLVAY PHARM GMBH·Filed 2007·Granted Jul 27, 2010·1 cites·17 claims
- 1272US2022378737A1Treatment of metabolic disorders in canine animalsBOEHRINGER INGELHEIM VETMEDICA GMBH·Filed 2022·Application pending·0 cites
- 1370US2023140631A1Treatment of metabolic disorders in feline animalsBOEHRINGER INGELHEIM VETMEDICA GMBH·Filed 2022·Application pending·0 cites
- 1467US2025268929A1Treatment of metabolic disorders in equine animalsBOEHRINGER INGELHEIM VETMEDICA GMBH·Filed 2025·Application pending·0 cites
- 1564US6770649B21-[1-(hetero)aryl-1-perhydroxyalkylmethyl]-piperazine compounds, process for their preparation and pharmaceutical compositions containing themSOLVAY PHARM GMBH·Filed 2002·Granted Aug 3, 2004·2 cites·12 claims
- 1662US2021069222A1Treatment of metabolic disorders in equine animalsBOEHRINGER INGELHEIM VETMEDICA GMBH·Filed 2020·Application pending·0 cites
- 1758US2009104126A1Sulfamate Compounds and Uses ThereofSOLVAY PHARM GMBH·Filed 2008·Application pending·0 cites
- 1857US2021128719A1Modular antigen transportation molecules and uses thereof in animalsBOEHRINGER INGELHEIM VETMEDICA GMBH·Filed 2020·Application pending·0 cites
- 1954US2007254863A1Use of CBx cannabinoid receptor modulators as potassium channel modulatorsANTEL JOCHEN·Filed 2007·Application pending·0 cites
- 2054US2020237794A1Treatment of metabolic disorders in equine animalsBOEHRINGER INGELHEIM VETMEDICA GMBH·Filed 2020·Application pending·0 cites
- 2152US9920101B2Modular antigen transportation molecules and uses therofBOEHRINGER INGELHEIM VETMEDICA GMBH·Filed 2015·Granted Mar 20, 2018·0 cites·33 claims
- 2252US2014303096A1Treatment of metabolic disorders in equine animalsREICHE DANIA BIRTE·Filed 2014·Application pending·0 cites
- 2351US10919945B2Modular antigen transportation molecules and uses therofBOEHRINGER INGELHEIM VETMEDICA GMBH·Filed 2018·Granted Feb 16, 2021·0 cites·1 claims
- 2448US7592344B2NK1 and NK2-antagonists and compositions and methods of using the sameSOLVAY PHARM GMBH·Filed 2006·Granted Sep 22, 2009·0 cites·16 claims
- 2547US10898568B2Modular antigen transportation molecules and uses thereof in animalsBOEHRINGER INGELHEIM VETMEDICA GMBH·Filed 2016·Granted Jan 26, 2021·0 cites·19 claims
- 2647US2005261292A1Pharmaceutical composition containing N-sulfamoyl-N'-arylpiperazines for the treatment or inhibition of obesity and related conditionsSOLVAY PHARM GMBH·Filed 2005·Application pending·0 cites
- 2744US7772225B2N-sulfamoyl-piperidineamides for the treatment or inhibition of obesity and related conditionsSOLVAY PHARM GMBH·Filed 2006·Granted Aug 10, 2010·0 cites·18 claims
- 2844US2007219214A1Dual NK2/NK3-antagonists, pharmaceutical compositions comprising them, and processes for their preparationSOLVAY PHARM GMBH·Filed 2007·Application pending·0 cites
- 2941US7547708B2N-sulfamoyl-N′-benzopyranpiperidine compounds and uses thereofSOLVAY PHARMACEUTICALS INC·Filed 2006·Granted Jun 16, 2009·0 cites·20 claims
- 3041US2007191357A1Methods of using potassium channel inhibiting compoundsANTEL JOCHEN·Filed 2006·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →